Tennessee lawmakers have inched closer to putting statewide rules around stem cell and regenerative medicine, with the House signing off on HB2246 on April 13. The bill would let physicians continue offering certain non-FDA-approved procedures for orthopedics, wound care and pain management, as long as the cellular products come from certified suppliers and patients sign detailed informed consent forms spelling out what they are getting into.
Where the bill stands
Backers in the House pitched the measure as a way to protect patients without shutting down access to treatments that some see as their last, best shot. "Stem cell therapy is a lifeline for many in our state, and this legislation protects patients while safeguarding access to innovative treatments," Rep. Chris Hurt said in a statement, according to WZTV. With House approval in hand, the bill now heads to the Senate for its turn in the spotlight.
Key requirements in the bill
According to the bill text, doctors could perform non-FDA-approved stem cell or regenerative-medicine therapies only when the treatment falls within the physician’s scope of practice and the cellular products meet strict sourcing, storage and testing standards. Products would have to be retrieved, manufactured and stored in a facility that is registered and regulated by the U.S. Food and Drug Administration or accredited by organizations such as the National Marrow Donor Program or the American Association of Tissue Banks, with pre- and post-thaw viability reports required before use.
The legislation also lays out timing: it specifies that the act would take effect for rule-promulgation as soon as it becomes law, and for all other purposes on July 1, 2026. Those details are spelled out in the HB2246 text on the Tennessee General Assembly.
How stem cell treatments are used now
Some stem cell procedures, especially hematopoietic (bone marrow) transplants, are long-established treatments for blood cancers such as leukemia and lymphoma, according to the American Cancer Society. Other regenerative uses are still considered experimental, and the Mayo Clinic has warned that hundreds of clinics offer unproven cellular therapies outside rigorous FDA studies.
That tension, between life-saving transplants and a looser marketplace of unproven offerings, is what lawmakers say HB2246 is trying to address.
Consent, advertising and penalties
The bill would force clinics to be blunt in their marketing, requiring a conspicuous notice in any advertisement that the therapy is not FDA-approved. It would also require written informed consent that lays out the nature of the treatment, anticipated results, risks and alternatives so patients are not relying on glossy brochures alone.
The Fiscal Review Committee reports that the measure’s fiscal impact on the state would be "not significant" and notes that the boards of medical examiners would be authorized to promulgate rules to enforce the new standards. The text further allows state licensing boards to discipline physicians and creates criminal penalties in a narrow set of intentional cases.
What is next
A companion Senate bill has already moved through committee and been placed on the Senate calendar for further action, according to the Tennessee Senate Republican Caucus. If the Senate signs off and Gov. Bill Lee approves it, rulemaking could start right away, with the rest of the law scheduled to kick in on July 1, 2026.
Legal implications
Beyond licensing and advertising rules, HB2246 would give regulators explicit authority to discipline physicians and would make certain intentional uses or sales of embryo- or fetus-derived materials a criminal offense under state law. How aggressively state boards and prosecutors choose to use those tools will ultimately decide what clinics can and cannot do inside Tennessee’s borders.
Supporters and providers say the proposal tries to walk a line between guarding patient safety and preserving room for innovation. The Senate’s next moves will decide whether those new guardrails actually make it into Tennessee law this year.
